TL;DR: 🟢 Positive (noninferiority) — individualized short-course antibiotics for VAP were noninferior to usual long courses (41% vs 44%) while cutting antibiotic side effects from 38% to 8%.
1. Publication
- Title: Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial
- Acronym: REGARD-VAP
- Year & Journal: The Lancet Respiratory Medicine, published January 22, 2024
- Citation: Mo Y, Booraphun S, Li AY, et al. Lancet Respir Med. 2024. doi:10.1016/S2213-2600(23)00418-6
2. Context & Rationale
Background: VAP is linked to excessive antibiotic use, antimicrobial resistance, prolonged hospitalization, and mortality as high as 40%. Current guidelines (WHO, IDSA, ESCMID) recommend a fixed 7-8 days, but the approach for identifying patients suitable for shorter courses is not clearly defined; a prior procalcitonin-guided meta-analysis only modestly reduced duration (13 to 11 days).
Research Question/Hypothesis: In adult VAP patients, is an individualized, clinical-response-guided short antibiotic course noninferior to usual long-course treatment for 60-day death or pneumonia recurrence?
3. Design & Methods
- Study Type: Multicenter, individually randomized, open-label, non-inferiority, phase 4 trial
- Setting & Centers: 39 ICUs in 6 hospitals, Nepal, Thailand, Singapore; May 2018–Dec 2022 (4-year trial)
- Population: 460 adults with VAP, SOFA≤10, not immunocompromised, no concurrent infection requiring >7 days antibiotics, receiving culture-directed antibiotics and MV ≥48h
- Intervention: Individualized short-course — antibiotics (IV, oral, nebulised) stopped as early as day 3-5 (up to 7 days) once fitness criteria met (defervescence 48h, stable BP without inotropes)
- Comparator: Usual care — minimum 8 days, exact duration beyond decided by treating physician
- Statistical Power & Follow-Up: Primary: composite of death or pneumonia recurrence within 60 days. Secondary: MV duration, ICU/hospital stay, antibiotic use duration, readmission, bloodstream infections, MDR acquisition.
4. Key Results
460 patients randomized.
Outcome | Individualized Short-Course | Usual Long-Course | Notes |
Death or pneumonia recurrence within 60d (primary) | 41% | 44% | Noninferiority demonstrated |
Antibiotic-related side effects | 8% | 38% | Substantially reduced with short-course |
5. Internal Validity Assessment
Multicenter (39 ICUs, 3 countries), individually randomized, adequately powered noninferiority trial conducted over 4 years. Overall: Strong — clean noninferiority result on the primary composite, with a large, clinically important reduction in antibiotic side effects as a genuine secondary benefit.
6. External Validity Assessment
Multicountry population specifically including low- and middle-income countries (Nepal, Thailand, Singapore) — an explicitly noted strength, since prior antibiotic-duration trials for VAP were "restricted mainly to high-income settings."
7. Strengths & Limitations
Strengths: Multicountry, LMIC-inclusive design filling a genuine evidence gap; individualized (clinical-response-guided) rather than fixed-duration approach; large reduction in antibiotic side effects; companion cost-effectiveness analysis published.
Limitations: Open-label design; trend toward increased VAP recurrence/relapse specifically with Gram-negative non-fermenting bacilli (Pseudomonas, Acinetobacter, Stenotrophomonas) noted in prior fixed-duration trials — a caveat for that specific pathogen subgroup.
8. Interpretation & Practice Impact
Supports individualized, clinical-response-guided short antibiotic courses for VAP over fixed long courses — noninferior for mortality/recurrence with a substantial reduction in antibiotic-related harm, and explicitly validated as deployable in LMIC settings per an SCCM Congress presentation.
9. Controversies & Subsequent Evidence
A companion economic analysis (Lancet Global Health, 2024) confirmed cost-effectiveness of the short-course strategy. Presented at SCCM's 2024 Critical Care Congress, where presenter Gyan K. Kayastha explicitly noted, "This can be used in developing country setting [and] low-income setting as well" — directly addressing global applicability.
10. Summary & Executive Takeaway
Summary: REGARD-VAP randomized 460 VAP patients across 39 ICUs in Nepal, Thailand, and Singapore to individualized short-course (clinical-response-guided, as early as day 3-5) or usual long-course (≥8 days) antibiotics. The composite of death or pneumonia recurrence at 60 days was noninferior (41% vs 44%), with antibiotic side effects dramatically reduced (38% to 8%).
Overall Takeaway: Individualized, clinical-response-guided short antibiotic courses for VAP are noninferior to usual long courses for mortality/recurrence while substantially reducing antibiotic-related harm — a genuinely practice-relevant, globally applicable (including LMIC settings) antimicrobial stewardship advance, with a caveat for Gram-negative non-fermenting bacilli infections warranting caution.
11. Bibliography
- Mo Y, West TE, MacLaren G, et al. REGARD-VAP protocol. BMJ Open. 2021;11:e050105.
- Cost-effectiveness of a short-course antibiotic treatment strategy for VAP: economic analysis of REGARD-VAP. Lancet Glob Health. 2024.
- Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality: patient-level meta-analysis. Lancet Infect Dis. 2018;18:95-107.